T-Cell-Based Cellular Immunotherapy of Multiple Myeloma: Current Developments.

ABSTRACT: T-cell-based cellular therapy was first approved in lymphoid malignancies (B-cell acute lymphoblastic leukemia and large B-cell lymphoma) and expanding its investigation and application both in hematological and non-hematological malignancies. Two anti-BCMA (B cell maturation antigen) CAR (Chimeric Antigen Receptor) T-cell therapies have been recently approved for relapsed and refractory multiple myeloma with excellent efficacy even in the heavily pre-treated patient population. This new therapeutic approach significantly changes our practice; however, there is still room for further investigation to optimize antigen receptor engineering, cell harvest/selection, treatment sequence, etc. They are also associated with unique adverse events, especially CRS (cytokine release syndrome) and ICAN

SUBMITTER: Simmons GL 

PROVIDER: S-EPMC9455067 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature